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Newcastle University, Newcastle-upon-Tyne, NE2 4HH, UKNeurodegenerative diseases present a major health chal-
lenge to the ageing population, and most are thought to
arise through a complex interplay between inherited
genetic variation and environmental triggers. Although
rare monogenic forms of common neurological disorders
exist, these account for <5% of the total number of cases.
Large-scale genome-wide association studies (GWAS) are
starting to have some success in identifying the major risk
alleles involved in several common neurodegenerative dis-
orders [1]. However, as researchmoves to the next phase of
GWAS, one needs to ask whether more emphasis should be
placed on phenotypic accuracy, rather than simply increas-
ing sample sizes.
The diagnosis of a late-onset neurological disease gener-
ally relies heavily on the clinical description provided by an
experienced neurologist. Specific diagnostic tests are rare,
and several autopsy case series have demonstrated a
diagnostic error rate approaching 10%, even in expert
hands [2,3]. Diagnostic revision also occurs in1/3 of cases
[4,5]. Phenotypic misclassification reduces the power to
detect a statistical association between a phenotype and
specific allele for a given sample size [6–9]. Although this is
primarily a clinical issue, the genetics community should
be concerned; it is also relevant for any human disease
where the clinical classification is not 100% accurate [8,9].There have been several approaches to try and deal with
the issue of diagnostic inaccuracy in neurodegenerative
diseases (Box 1). In silico modelling has shown that
increasing the sample size counterbalances diagnostic
error [10], but that the relationship between statistical
power and diagnostic accuracy is not linear; in addition,
the sample size required to generate reasonable power
increases dramatically with reduced diagnostic accuracy
[10]. For strong genetic effects, the precise diagnosis might
not be a key issue. For example, evenwhen 15% of cases are
incorrectly classified as Alzheimer disease, a study of 500
cases and 500 controls would have >70% power to detect
the well-established association with the e4 APOE allele
(Online Supplementary Material Figure S1). However, the
detection of hitherto unknownmodest disease associations
at the whole-genome level presents a greater challenge
[11]. For common genetic variants exerting a modest effect
[where the genome relative risk (GRR) is 1.3], a diagnostic
error rate of 2% has little effect on statistical power
(Figure 1a). However,>2% diagnostic error has a dramatic
effect on power, especially when attention is drawn to
lower-penetrance alleles (i.e. GRR 1.1), as proposed for
many complex traits. This is further compounded when
less frequent but equally plausible genetic variants (with a
minor allele frequency 10%) are considered, which are
highly sensitive to diagnostic errors (Figure 1b). Studies of
rarer disease phenotypes (affecting <1 in 1000 adults)
Box 1. Approaches to counteract phenotypic
misclassification in neurodegenerative disease
 Using standardised and validated clinical diagnostic criteria
 Use of additional clinical data to substantiate the diagnosis (use of
‘endophenotypes’; such as cognitive, motor-system and beha-
vioural rating scales, biochemical tests or imaging parameters)
 Studying prospective cohorts (thus avoiding retrospective, third-
hand clinical evaluation, and enabling diagnostic re-evaluation as
the disease progresses).
 Exclusively studying cases with a histological diagnosis (e.g.
biopsy positive or autopsy case series).
 Increase the size of the study.
Update Trends in Genetics Vol.25 No.11present an even greater challenge (Figure 1c). This
includes well-recognized disorders [such as amyotrophic
lateral sclerosis (ALS), or progressive supranuclear palsy
(PSP)], or clinical subgroups of common disorders (such asFigure 1. Power to detect a genetic association in the context of diagnostic errors. In e
1  105. Varying this parameter has negligible impact on power and/or optimal sample
an association between a common allele (allele frequency = 0.5; GRR = 1.1– 1.3 under a
degrees of diagnostic error at P < 5  107. Disease frequency = 0.01. (b) Power to detec
20 000 cases and 20 000 controls with varying degrees of diagnostic error at P < 5  107
allele (frequency = 0.125, GRR = 1.3) and diseases of different prevalence (0.01, 0.001, 0.0
P < 5  107. (d) Ratio of the number of inaccurately phenotyped cases (nerror) to the n
between an allele (frequency = 0.1, varying GRR from 1.1 to 1.3) and a disease (frequenc
calculations used PAWE-PH Phenotype Edition [10].cases of Parkinson’s diseasewith dementia), where distinct
genetic factors are thought to modulate the phenotype.
So should the sample size simply be increased, or should
the samples be chosen more carefully by more accurate
phenotyping? Reduced diagnostic accuracy is associated
with an increase in the number of samples required for a
study of equivalent power, irrespective of the GRR
(Figure 1d). Thus, to achieve the same effect, investigators
could either improve the phenotypic accuracy and remove
false-positive cases from an existing cohort, or they could
inflate the number of cases by up to 400-fold to compensate
for the diagnostic errors of up to 20% (Figure 1d). We argue
that it is more cost effective to improve phenotypic accuracy
thanit isto increasethesamplesize.Forexample,evenwhen
consideringalleleswithamodesteffect (GRR = 1.3), increas-
ing diagnostic accuracy from 90% to 95% would reduce the
number of affected individuals needed by threefold whileach example, the probability of affected individuals being classified as controls is
size for diseases that are present in <10% of the population [10]. (a) Power to detect
multiplicative model) and disease in 20 000 cases and 20 000 controls with varying
t an association between alleles of different frequency (0.5, 0.25, 0.1) and disease in
. GRR = 1.3, disease frequency = 0.01. (c) Power to detect an association between an
001) in 20 000 cases and 20 000 controls with varying degrees of diagnostic error at
umber of accurately phenotyped cases (nno error) required to detect an association
y = 0.01) with 95% power at varying degrees of diagnostic error at P < 5  107. All
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the absolute number of cases required for 95% power at
P < 1  107 will be in excess of 1 million for samples diag-
nosedwith<99%accuracy (OnlineSupplementaryMaterial
Figure S2). This might never be feasible, especially when
genetic and environmental variations across the globe are
considered.Asrarer riskalleles for less commondiseasesare
sought, practical problems with accurate phenotyping will
become a major limiting factor to these studies.
Although quantifying phenotypic accuracy can, in itself,
present challenges, there are good examples where the cost
effectiveness can be evaluated. Single photon emission com-
puted tomography (SPECT) brain imaging with the ligand
(123)I-2beta-carbometoxy-3beta-(4-iodophenyl)-N-(3-fluor-
opropyl)-nortropane((123)I-FP-CIT, has a specificity of
100% for a diagnosis of degenerative parkinsonism [12],
although this test cannot reliably differentiate Parkinson’s
disease from atypical parkinsonian disorders, such as PSP.
Furthermore, in the differential diagnosis of dementia, an
abnormal FP–CIT scanhas a specificity of 90% for excluding
non-DementiawithLewy bodies (DLB) dementia [13]. Intri-
guingly, each FP–CIT scan costs about the same as a state-
of-the art genome-wide SNP array (£500). For biologically
plausible risk alleles with a minor frequency of 10% con-
ferring a GRR of 1.3, increasing diagnostic accuracy by 10%
wouldmean genotyping8000 rather than750 000 cases.
For relatively uncommon neurodegenerative diseases, such
as ALS (which has a prevalence 1 in 20 000) and PSP
(affecting 5 in 100 000), it might never be possible to
assemble cohorts with >100 000 cases from a genetically
homogeneous population; studies of uncommon alleles with
modest effects will only be possible with an exceptionally
high diagnostic accuracy, placing greater emphasis on
autopsy-based series. This also applies to phenotypic sub-
categories of more common phenotypes if distinct genetic
mechanisms are postulated.
Crucially, the same level of accuracy is not required
for control subjects, where clinical misclassification of
an affected individual as unaffected has less impact on
statistical power [10]. This is reassuring for late-onset
neurodegenerative disease, where there is always the risk
that a currently asymptomatic individual will develop
clinical features in the future. Providing the disease is
rare (<10% of the population), the age-related penetrance
is not a major concern [10].
Now that GWAS has helped to identify the ‘low hanging
fruit’ in complex disease (i.e. common alleles with strong
genetic effects), the emphasis shifts to the detection of the
20–100 low penetrance disease-specific variants thought
to underpin most common complex traits, some of which
might contribute to interindividual phenotypic variability.
To accomplish this, the approach needs to change.
Although current aspirations have been fuelled, in part,
by technological advances in molecular genetics, horizons
for some diseases will be restricted by inaccurate clinical
diagnosis. Several other factors currently limit one’s ability
to detect new neurodegenerative disease genes, including488the limited resolution of current studies to detect rarer
genetic variants, epistatic genetic and epigenetic effects,
and the role of a changing environment. Some of these
issues will be difficult to resolve, and also costly, so perhaps
the emphasis should now move towards improving pheno-
typic accuracy, because this will enrich the yield using
current molecular approaches.
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